Novoprotein Scientific Inc. (SHA:688137)

Novoprotein Scientific Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	799.16	647.35	863.7	929.92	189.39	68.68
Short-Term Investments	-	1,154	404.51	-	-	-
Trading Asset Securities	-	-	621.7	966.85	-	25.14
Cash & Short-Term Investments	799.16	1,801	1,890	1,897	189.39	93.83
Cash Growth	19.46%	-4.69%	-0.36%	901.50%	101.86%	2063.73%
Accounts Receivable	71.68	62.02	79.97	134.66	96.58	23.03
Other Receivables	3.7	10.91	3.45	10.35	2.95	7.53
Receivables	75.38	72.93	83.42	145	99.53	30.56
Inventory	68.47	76.08	84.97	77.08	37.19	18.71
Other Current Assets	970.63	5.95	11.9	16.29	6.11	2.37
Total Current Assets	1,914	1,956	2,070	2,135	332.22	145.47
Property, Plant & Equipment	194.41	170.14	133.92	134.98	137.95	12.77
Long-Term Investments	10	10	-	-	-	-
Other Intangible Assets	17.9	18.21	18.71	18.18	6.71	0.11
Long-Term Deferred Tax Assets	40.79	31.22	27.94	18.51	12.96	10.7
Long-Term Deferred Charges	8.89	10.78	9.69	5.6	4.93	2.62
Other Long-Term Assets	9.61	21.48	38.45	21.05	18.33	0.27
Total Assets	2,195	2,218	2,299	2,333	513.1	171.93
Accounts Payable	40.53	28.26	17.94	20.9	23.64	8.22
Accrued Expenses	11.96	14.82	11.82	18.03	21.21	18.92
Current Portion of Leases	9.36	17.67	13.87	13.95	8.69	-
Current Income Taxes Payable	3.16	0.01	1.34	5.01	4.52	15.55
Current Unearned Revenue	5.75	5.02	4.19	4.81	11.61	13.24
Other Current Liabilities	3.79	1.39	0.97	1.32	2.11	11.4
Total Current Liabilities	74.54	67.17	50.12	64.02	71.78	67.33
Long-Term Leases	39.02	48.75	59.44	69.2	78.34	-
Long-Term Unearned Revenue	1.22	0.52	0.87	-	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	3.21	1.51
Total Liabilities	114.78	116.44	110.43	133.22	153.33	68.83
Common Stock	70.18	70.18	70.18	70.18	52.63	15.88
Additional Paid-In Capital	1,973	1,963	1,950	1,940	208.13	31.51
Retained Earnings	49.5	78.36	167.86	190.1	98.82	55.51
Treasury Stock	-11.96	-10.35	-	-	-	-
Comprehensive Income & Other	0.19	0.15	0.18	0.18	0.19	0.2
Shareholders' Equity	2,080	2,102	2,188	2,200	359.77	103.1
Total Liabilities & Equity	2,195	2,218	2,299	2,333	513.1	171.93
Total Debt	48.38	66.42	73.31	83.15	87.04	-
Net Cash (Debt)	750.78	1,735	1,817	1,814	102.36	93.83
Net Cash Growth	26.19%	-4.50%	0.16%	1671.86%	9.09%	28293.51%
Net Cash Per Share	10.74	24.87	25.46	31.79	2.56	5.91
Filing Date Shares Outstanding	69.77	69.83	70.18	70.18	52.63	15.88
Total Common Shares Outstanding	69.77	69.83	70.18	70.18	52.63	15.88
Working Capital	1,839	1,889	2,020	2,071	260.44	78.14
Book Value Per Share	29.82	30.10	31.19	31.35	6.84	6.49
Tangible Book Value	2,063	2,083	2,170	2,182	353.06	102.99
Tangible Book Value Per Share	29.56	29.84	30.92	31.09	6.71	6.48
Machinery	-	78.93	64.44	59.66	42.2	21.33
Construction In Progress	-	74.95	31.26	17.73	21.16	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.